Geode Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-767,117
| Closed | -$1.42M | – | 4846 |
|
|
2023
Q1 | $1.42M | Buy |
767,117
+96,655
| +14% | +$120K | ﹤0.01% | 3181 |
|
|
2022
Q4 | $744K | Buy |
670,462
+13,180
| +2% | +$18.8K | ﹤0.01% | 3498 |
|
|
2022
Q3 | $1.54M | Buy |
657,282
+33,007
| +5% | +$117K | ﹤0.01% | 3185 |
|
|
2022
Q2 | $1.89M | Buy |
624,275
+27,660
| +5% | +$135K | ﹤0.01% | 3129 |
|
|
2022
Q1 | $4.05M | Sell |
596,615
-26,261
| -4% | -$187K | ﹤0.01% | 2921 |
|
|
2021
Q4 | $5.2M | Buy |
622,876
+8,446
| +1% | +$69.6K | ﹤0.01% | 2876 |
|
|
2021
Q3 | $4.57M | Buy |
614,430
+84,915
| +16% | +$526K | ﹤0.01% | 2957 |
|
|
2021
Q2 | $3.6M | Buy |
529,515
+186,990
| +55% | +$1.55M | ﹤0.01% | 3089 |
|
|
2021
Q1 | $3.52M | Buy |
342,525
+75,218
| +28% | +$824K | ﹤0.01% | 2954 |
|
|
2020
Q4 | $1.87M | Buy |
267,307
+4,367
| +2% | +$34K | ﹤0.01% | 3122 |
|
|
2020
Q3 | $2.15M | Buy |
262,940
+16,796
| +7% | +$104K | ﹤0.01% | 2845 |
|
|
2020
Q2 | $1.7M | Sell |
246,144
-1,384
| -0.6% | -$7.46K | ﹤0.01% | 2927 |
|
|
2020
Q1 | $1.18M | Sell |
247,528
-12,432
| -5% | -$71.6K | ﹤0.01% | 2947 |
|
|
2019
Q4 | $2.27M | Buy |
259,960
+36,548
| +16% | +$198K | ﹤0.01% | 2933 |
|
|
2019
Q3 | $743K | Buy |
223,412
+7,712
| +4% | +$30.9K | ﹤0.01% | 3345 |
|
|
2019
Q2 | $1.07M | Buy |
215,700
+15,544
| +8% | +$82.5K | ﹤0.01% | 3221 |
|
|
2019
Q1 | $1.24M | Buy |
200,156
+38,735
| +24% | +$187K | ﹤0.01% | 3072 |
|
|
2018
Q4 | $543K | Buy |
161,421
+20,638
| +15% | +$96.4K | ﹤0.01% | 3347 |
|
|
2018
Q3 | $914K | Buy |
140,783
+21,008
| +18% | +$156K | ﹤0.01% | 3256 |
|
|
2018
Q2 | $917K | Buy |
119,775
+16,577
| +16% | +$239K | ﹤0.01% | 3223 |
|
|
2018
Q1 | $2.31M | Buy |
103,198
+1,541
| +2% | +$34.2K | ﹤0.01% | 2686 |
|
|
2017
Q4 | $1.3M | Buy |
101,657
+359
| +0.4% | +$5.28K | ﹤0.01% | 2988 |
|
|
2017
Q3 | $1.58M | Buy |
101,298
+372
| +0.4% | +$5.26K | ﹤0.01% | 2877 |
|
|
2017
Q2 | $1.42M | Buy |
100,926
+29,358
| +41% | +$628K | ﹤0.01% | 2924 |
|
|
2017
Q1 | $1.57M | Buy |
+71,568
| New | +$1.52M | ﹤0.01% | 2786 |
|
Other funds holding JNCE
Geode Capital Management's JNCE Position: Q2 2023 in Review
Geode Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 767,117 shares — an estimated $1.42M sold.
Geode Capital Management first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $5.2M in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Geode Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Geode Capital Management sold 767,117 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.42M.
- Geode Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Geode Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $5.2M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.